Arcus Biosciences, Inc. (RCUS)
29.21
-1.38
(-4.51%)
USD |
NYSE |
Aug 28, 16:00
29.18
-0.03
(-0.10%)
Pre-Market: 20:00
Arcus Biosciences Free Cash Flow : -475.00M for June 30, 2026
Free Cash Flow Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| June 30, 2026 | -475.00M |
| March 31, 2026 | -489.00M |
| December 31, 2025 | -484.00M |
| September 30, 2025 | -464.00M |
| June 30, 2025 | -342.00M |
| March 31, 2025 | -303.00M |
| December 31, 2024 | -176.00M |
| September 30, 2024 | -169.00M |
| June 30, 2024 | -267.00M |
| March 31, 2024 | -235.00M |
| December 31, 2023 | -330.00M |
| September 30, 2023 | -306.12M |
| June 30, 2023 | -315.40M |
| March 31, 2023 | -320.21M |
| December 31, 2022 | 432.00M |
| September 30, 2022 | 431.51M |
| Date | Value |
|---|---|
| June 30, 2022 | 452.17M |
| March 31, 2022 | 438.92M |
| December 31, 2021 | -282.25M |
| September 30, 2021 | -263.04M |
| June 30, 2021 | 13.77M |
| March 31, 2021 | 69.64M |
| December 31, 2020 | 108.12M |
| September 30, 2020 | 149.85M |
| June 30, 2020 | -93.30M |
| March 31, 2020 | -89.41M |
| December 31, 2019 | -75.39M |
| September 30, 2019 | -73.08M |
| June 30, 2019 | -58.03M |
| March 31, 2019 | -49.90M |
| December 31, 2018 | -46.74M |
| September 30, 2018 | -64.43M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| Halozyme Therapeutics, Inc. | 806.22M |
| AVITA Medical, Inc. | -25.21M |
| Iovance Biotherapeutics, Inc. | -296.40M |
| Editas Medicine, Inc. | -120.55M |
| Recursion Pharmaceuticals, Inc. | -354.26M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -119.00M |
| Cash from Investing (Quarterly) | 52.00M |
| Cash from Financing (Quarterly) | 16.00M |
| Free Cash Flow Per Share (Quarterly) | -0.9437 |
| Free Cash Flow to Equity (Quarterly) | -120.00M |
| Free Cash Flow to Firm (Quarterly) | -116.00M |
| Free Cash Flow Yield | -13.65% |